Insmed (NASDAQ:INSM – Get Free Report) and Applied Therapeutics (NASDAQ:APLT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Insider & Institutional Ownership
98.3% of Applied Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Insmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insmed | 1 | 1 | 23 | 1 | 2.92 |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Insmed presently has a consensus target price of $196.52, suggesting a potential upside of 62.20%. Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics’ higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Insmed.
Valuation and Earnings
This table compares Insmed and Applied Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insmed | $606.42 million | 43.83 | -$1.28 billion | ($2.82) | -42.96 |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
Applied Therapeutics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Insmed and Applied Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insmed | -39.85% | -96.38% | -32.55% |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
Summary
Insmed beats Applied Therapeutics on 8 of the 15 factors compared between the two stocks.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
About Applied Therapeutics
Applied Therapeutics is a biotechnology company focused on developing small-molecule medicines for rare metabolic and other serious diseases. Founded in 2016, the company is based in New York and was founded by Shoshana Shendelman, who has served as its chief executive officer. The company’s pipeline has centered on govorestat, an investigational inhibitor of the enzyme aldose reductase. Applied Therapeutics has studied the drug in conditions including classic galactosemia, SORD deficiency and PMM2-CDG, disorders that can affect multiple body systems and have limited treatment options.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
